/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Biomarin Pharmaceutical (BMRN) has never paid a dividend. The business does generate free cash flow of $767 million, so the absence of a dividend is a capital-allocation choice rather than an inability to pay. All figures are computed from company filings; this is analysis, not investment advice.
No. Biomarin Pharmaceutical (BMRN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.
It largely does not. Biomarin Pharmaceutical pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.
On the numbers, yes. Biomarin Pharmaceutical generated $767 million of free cash flow, which is about $3.88 per share. If it paid out half of that, the dividend would be roughly $1.94 per share, a yield of about 3.2% at the current price. That is an illustration of capacity, not a prediction: the company has given no indication it intends to pay one.
Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Biomarin Pharmaceutical.
SourceDividend analysis computed from the 10-Q filed 5 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 23 Jul 2026. How this is calculated.
Fiscal year ends Dec. Earnings payout = dividends / net income. FCF payout = dividends / FCF. Yield = TTM DPS / price.